Corvus Pharmaceuticals Inc (CRVS) concluded trading on Wednesday at a closing price of $4.70, with 14.06 million shares of worth about $66.1 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 146.07% during that period and on December 18, 2024 the price saw a loss of about -36.40%. Currently the company’s common shares owned by public are about 62.58M shares, out of which, 50.33M shares are available for trading.
Stock saw a price change of -42.05% in past 5 days and over the past one month there was a price change of -43.65%. Year-to-date (YTD), CRVS shares are showing a performance of 167.05% which increased to 205.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.30 but also hit the highest price of $10.00 during that period. The average intraday trading volume for Corvus Pharmaceuticals Inc shares is 800.81K. The stock is currently trading -41.97% below its 20-day simple moving average (SMA20), while that difference is down -41.88% for SMA50 and it goes to 15.04% higher than SMA200.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) currently have 62.58M outstanding shares and institutions hold larger chunk of about 28.59% of that.
The stock has a current market capitalization of $302.01M and its 3Y-monthly beta is at 0.98. It has posted earnings per share of -$0.93 in the same period. It has Quick Ratio of 0.92 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRVS, volatility over the week remained 15.68% while standing at 8.60% over the month.
Stock’s fiscal year EPS is expected to drop by -65.36% while it is estimated to increase by 49.24% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on August 18, 2023 offering an Outperform rating for the stock and assigned a target price of $7 to it. Coverage by Jefferies stated Corvus Pharmaceuticals Inc (CRVS) stock as a Buy in their note to investors on December 01, 2021, suggesting a price target of $8 for the stock. On May 27, 2021, Cantor Fitzgerald Initiated their recommendations, while on February 10, 2021, Mizuho Downgrade their ratings for the stock with a price target of $4. Stock get a Buy rating from Mizuho on September 12, 2019.
